The regenerative medicine industry is estimated to be valued at US$ 13385.6 million in 2023. The industry is expected to reach US$ 73,084.2 million by 2033, developing at a CAGR of 18.5%.
Regenerative Medicine Industry Trend Analysis
| Attributes | Key Insights |
|---|---|
| Regenerative Medicine Industry Estimated Size in 2023 | US$ 13,385.6 million |
| Projected Industry Value in 2033 | US$ 73,084.2 million |
| Value-based CAGR from 2023 to 2033 | 18.5% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
A study by our analysts found that a 16.2% CAGR was experienced between 2017 and 2022 in the regenerative medicine industry. Global demand for regenerative medicine is predicted to increase at a CAGR of 18.5% from 2023 to 2033.
The growth of the regenerative medicine industry is directly linked to the rising prevalence of chronic diseases along with the rise in wounds and injuries in the booming population. The prevalence of diseases in the increasing population is directly linked to the growth of the regenerative medicine industry.
Several regulatory laws provide technical guidance for regenerative medicine product quality. These therapy types substantially impact health and govern the approval of regenerative medicine products.
Increased biopharma funding has contributed to the growth of the regenerative medicine industry. Multinational corporations are beginning to develop long-term business models. Increase in pet adoption, veterinary professionals are becoming interested in regenerative medicine. The demand for allogeneic stem cell therapy has increased for its safe and effective effects on animals.
| Historical CAGR from 2017 to 2022 | 16.2% |
|---|---|
| Forecast CAGR from 2023 to 2033 | 18.5% |
Principal Consultant
Forecast CAGRs from 2023 to 2033
| Australia | 11.5% |
|---|---|
| China | 27.2% |
| India | 15.5% |
| The United Kingdom | 13.2% |
The growing aging population, the adoption rate of regenerative medicines, and the prevalence of chronic diseases are contributing factors boosting the regenerative medicine industry in China. China is expected to account for a CAGR of 27.2% through 2033.
The government in China has been actively promoting the development of regenerative medicine through various initiatives and funding programs. Initiatives like the 'Made in China 2025' plan and the 'Healthy China 2030' plan prioritize the growth of biotechnology and healthcare industries, including regenerative medicine.
The demand for regenerative medicine will continue to increase in China in consideration of the above factors, promoting the value of the overall regenerative medicine Industry.
The government in Australia has been actively supporting regenerative medicine research and development through various initiatives and grants. Australian scientists, biotech companies, and biomedical engineers have been at the forefront of advancements in regenerative medicine, propelling the industry's demand. Australia is expected to expand at a CAGR of 11.5% through 2033.
The presence of a high-quality healthcare system, experienced clinical research organizations (CROs), and a regulatory framework are expected to support the market growth. Australia has a well-defined regulatory framework for regenerative medicine products, providing a clear research, development, and commercialization pathway.
India is one of the leading manufacturers of regenerative medicine. India is anticipated to rise at a CAGR of 15.5% during the forecast period due to the rising penetration of prominent manufacturers. Regenerative medicine therapies, such as stem cell-based treatments, are gaining popularity among medical tourists in the country.
The government in India has shown interest in promoting regenerative medicine and stem cell research. Initiatives such as the Department of Biotechnology's 'Stem Cell Research and Regenerative Medicine' program and the 'Make in India' campaign have provided support and incentives to the regenerative medicine industry.
The growth of the regenerative medicine industry is attributed to extensive, cutting-edge research and development being carried out in the United Kingdom. The United Kingdom is expected to expand at a CAGR of 13.2% through 2033.
Large investment allocations by both government and private players are contributing to the growth of the industry in the United Kingdom. The presence of the biotechnology and pharmaceutical industry includes established companies and startups focused on regenerative medicine in the country.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Category | Expected Revenue Share in 2023 |
|---|---|
| Tissue Engineering by Therapy | 43% |
| Oncology by Application | 30% |
Tissue engineering segment is expected to accumulate a market share of 43% in 2023. Tissue engineering is popular because of its adoption in tissue repair, thus accelerating Industry growth.
Tissue engineering in regenerative medicine finds applications in various medical fields, including orthopedics, cardiology, neurology, dermatology, and more. It is used for the regeneration of bone, cartilage, skin, blood vessels, and even complex organs like the heart and liver. Tissue engineering in the regenerative medicine market is highly regulated to ensure the safety and efficacy of products.
Oncology is expected to account for a value share of 40% as of 2023. The prevalence of cancer worldwide has driven this segment to be a dominant fragment, propelling sales of the overall regenerative medicine Industry.
Developing and testing regenerative medicine approaches in oncology are active areas of research and clinical trials. Regenerative medicines offer the potential to repair and regenerate these damaged tissues, improving the quality of life for cancer patients.
With several competitors in regenerative medicine, the overall industry is fragmented. To meet consumer demand and expand their customer base, these companies are implementing methods such as divestiture, partnerships and collaborations, and new therapy launches.
Some of the developments by players in the regenerative medicine industry are given below
| Attributes | Details |
|---|---|
| Estimated Industry Size in 2023 | US$ 13385.6 million |
| Projected Industry Valuation in 2033 | US$ 73084.2 million |
| Value-based CAGR 2023 to 2033 | 18.5% |
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Industry Analysis | Value in US$ billion |
| Key Regions Covered |
|
| Key Industry Segments Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
The regenerative medicine industry is expected to reach US$ 13385.6 million in 2023.
The market for regenerative medicine is set to expand by a CAGR of 18.5% by 2033.
The regenerative medicine industry is forecast to reach US$ 73084.2 million by 2033.
A significant share of profits will likely come from the Industry in North America.
The popularity of tissue engineering is expected to grow through 2033.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Industry Analysis and Outlook 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Therapy Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Therapy Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapy Type, 2023 to 2033
5.3.1. Cell Therapy
5.3.1.1. Autologous Cell Therapy
5.3.1.2. Allogenic Cell Therapy
5.3.2. Stem Cell Therapy
5.3.2.1. Allogeneic Stem Cell Therapy
5.3.2.2. Autologous Stem Cell Therapy
5.3.3. Tissue-engineering
5.3.4. Gene Therapy
5.4. Y-o-Y Growth Trend Analysis By Therapy Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Therapy Type, 2023 to 2033
6. Global Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Application
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Application, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2023 to 2033
6.3.1. Wound Care
6.3.2. Musculoskeletal
6.3.3. Oncology
6.3.4. Dental
6.3.5. DMD (Duchenne Muscular Dystrophy)
6.3.6. Hepatological Diseases
6.3.7. Inflammatory & Autoimmune Diseases
6.3.8. Other Therapeutic Applications
6.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033
7. Global Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Western Europe
7.3.4. Eastern Europe
7.3.5. South Asia and Pacific
7.3.6. East Asia
7.3.7. Middle East and Africa
7.4. Market Attractiveness Analysis By Region
8. North America Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. The USA
8.2.1.2. Canada
8.2.2. By Therapy Type
8.2.3. By Application
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Therapy Type
8.3.3. By Application
8.4. Key Takeaways
9. Latin America Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Therapy Type
9.2.3. By Application
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Therapy Type
9.3.3. By Application
9.4. Key Takeaways
10. Western Europe Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. United Kingdom
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Western Europe
10.2.2. By Therapy Type
10.2.3. By Application
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Therapy Type
10.3.3. By Application
10.4. Key Takeaways
11. Eastern Europe Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Poland
11.2.1.2. Russia
11.2.1.3. Czech Republic
11.2.1.4. Romania
11.2.1.5. Rest of Eastern Europe
11.2.2. By Therapy Type
11.2.3. By Application
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Therapy Type
11.3.3. By Application
11.4. Key Takeaways
12. South Asia and Pacific Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Bangladesh
12.2.1.3. Australia
12.2.1.4. New Zealand
12.2.1.5. Rest of South Asia and Pacific
12.2.2. By Therapy Type
12.2.3. By Application
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Therapy Type
12.3.3. By Application
12.4. Key Takeaways
13. East Asia Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Therapy Type
13.2.3. By Application
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Therapy Type
13.3.3. By Application
13.4. Key Takeaways
14. Middle East and Africa Industry Analysis and Outlook 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Therapy Type
14.2.3. By Application
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Therapy Type
14.3.3. By Application
14.4. Key Takeaways
15. Key Countries Industry Analysis and Outlook
15.1. USA
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Therapy Type
15.1.2.2. By Application
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Therapy Type
15.2.2.2. By Application
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Therapy Type
15.3.2.2. By Application
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Therapy Type
15.4.2.2. By Application
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Therapy Type
15.5.2.2. By Application
15.6. United Kingdom
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Therapy Type
15.6.2.2. By Application
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Therapy Type
15.7.2.2. By Application
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Therapy Type
15.8.2.2. By Application
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Therapy Type
15.9.2.2. By Application
15.10. Poland
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Therapy Type
15.10.2.2. By Application
15.11. Russia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Therapy Type
15.11.2.2. By Application
15.12. Czech Republic
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Therapy Type
15.12.2.2. By Application
15.13. Romania
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Therapy Type
15.13.2.2. By Application
15.14. India
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Therapy Type
15.14.2.2. By Application
15.15. Bangladesh
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Therapy Type
15.15.2.2. By Application
15.16. Australia
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Therapy Type
15.16.2.2. By Application
15.17. New Zealand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Therapy Type
15.17.2.2. By Application
15.18. China
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Therapy Type
15.18.2.2. By Application
15.19. Japan
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Therapy Type
15.19.2.2. By Application
15.20. South Korea
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Therapy Type
15.20.2.2. By Application
15.21. GCC Countries
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Therapy Type
15.21.2.2. By Application
15.22. South Africa
15.22.1. Pricing Analysis
15.22.2. Market Share Analysis, 2022
15.22.2.1. By Therapy Type
15.22.2.2. By Application
15.23. Israel
15.23.1. Pricing Analysis
15.23.2. Market Share Analysis, 2022
15.23.2.1. By Therapy Type
15.23.2.2. By Application
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Therapy Type
16.3.3. By Application
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. 3M
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Allergan plc
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. Amgen, Inc.
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Aspect Biosystems
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. bluebird bio
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Kite Pharma
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Integra LifeSciences Holdings Corporation
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. MEDIPOST Co., Ltd.
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. Anterogen Co., Ltd.
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. MiMedx Group
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
17.1.11. Misonix, Organogenesis Inc.
17.1.11.1. Overview
17.1.11.2. Product Portfolio
17.1.11.3. Profitability by Market Segments
17.1.11.4. Sales Footprint
17.1.11.5. Strategy Overview
17.1.11.5.1. Marketing Strategy
17.1.12. Orthocell Limited
17.1.12.1. Overview
17.1.12.2. Product Portfolio
17.1.12.3. Profitability by Market Segments
17.1.12.4. Sales Footprint
17.1.12.5. Strategy Overview
17.1.12.5.1. Marketing Strategy
17.1.13. Corestem, Inc.
17.1.13.1. Overview
17.1.13.2. Product Portfolio
17.1.13.3. Profitability by Market Segments
17.1.13.4. Sales Footprint
17.1.13.5. Strategy Overview
17.1.13.5.1. Marketing Strategy
17.1.14. Spark Therapeutics
17.1.14.1. Overview
17.1.14.2. Product Portfolio
17.1.14.3. Profitability by Market Segments
17.1.14.4. Sales Footprint
17.1.14.5. Strategy Overview
17.1.14.5.1. Marketing Strategy
17.1.15. APAC Biotech
17.1.15.1. Overview
17.1.15.2. Product Portfolio
17.1.15.3. Profitability by Market Segments
17.1.15.4. Sales Footprint
17.1.15.5. Strategy Overview
17.1.15.5.1. Marketing Strategy
17.1.16. Shenzhen Sibiono
17.1.16.1. Overview
17.1.16.2. Product Portfolio
17.1.16.3. Profitability by Market Segments
17.1.16.4. Sales Footprint
17.1.16.5. Strategy Overview
17.1.16.5.1. Marketing Strategy
17.1.17. GeneTech Co., Ltd.
17.1.17.1. Overview
17.1.17.2. Product Portfolio
17.1.17.3. Profitability by Market Segments
17.1.17.4. Sales Footprint
17.1.17.5. Strategy Overview
17.1.17.5.1. Marketing Strategy
17.1.18. Smith & Nephew plc
17.1.18.1. Overview
17.1.18.2. Product Portfolio
17.1.18.3. Profitability by Market Segments
17.1.18.4. Sales Footprint
17.1.18.5. Strategy Overview
17.1.18.5.1. Marketing Strategy
17.1.19. Stryker Corporation
17.1.19.1. Overview
17.1.19.2. Product Portfolio
17.1.19.3. Profitability by Market Segments
17.1.19.4. Sales Footprint
17.1.19.5. Strategy Overview
17.1.19.5.1. Marketing Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
Regenerative Medicine Market
